Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.40 +0.01 (+2.60%)
As of 07/7/2026 03:58 PM Eastern
Compare

MDNA vs. GXE, CGC, WMD, EQ, and SGW

Should you buy Medicenna Therapeutics stock or one of its competitors? MarketBeat compares Medicenna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medicenna Therapeutics include Gear Energy (GXE), Canadian Gold (CGC), WeedMD (WMD), EQ (EQ), and Shoal Games (SGW). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to Gear Energy?

Medicenna Therapeutics (TSE:MDNA) and Gear Energy (TSE:GXE) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -219.30% -32.80%
Gear Energy 5.77%3.52%4.84%

0.4% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 2.4% of Gear Energy shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Comparatively, 7.6% of Gear Energy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A

Medicenna Therapeutics has a beta of 2.960355, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Gear Energy has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.34 beat Gear Energy's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Gear Energy Neutral

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Canadian Gold (CVE:CGC) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.34 beat Canadian Gold's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Canadian Gold Neutral
Medicenna Therapeutics Neutral

0.3% of Canadian Gold shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 43.3% of Canadian Gold shares are held by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Canadian GoldN/A -92.98% -48.06%
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

Canadian Gold has a beta of -1.586234, meaning that its share price is 259% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.960355, meaning that its share price is 196% more volatile than the broader market.

Summary

Canadian Gold and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

Medicenna Therapeutics (TSE:MDNA) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.34 beat WeedMD's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Medicenna Therapeutics Neutral
WeedMD Neutral

Medicenna Therapeutics has higher earnings, but lower revenue than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -219.30% -32.80%
WeedMD N/A N/A N/A

Summary

Medicenna Therapeutics and WeedMD tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to EQ?

EQ (CVE:EQ) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

EQ has a net margin of -11.73% compared to Medicenna Therapeutics' net margin of -533,640.00%. EQ's return on equity of 50.96% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
EQ-11.73% 50.96% -18.43%
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

EQ has a beta of -0.011235, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Medicenna Therapeutics has a beta of 2.960355, meaning that its stock price is 196% more volatile than the broader market.

0.1% of EQ shares are held by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are held by institutional investors. 12.8% of EQ shares are held by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

EQ has higher revenue and earnings than Medicenna Therapeutics. EQ is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EQC$10.54M6.27-C$4.66M-C$0.02N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.34 beat EQ's score of 0.00 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
EQ Neutral
Medicenna Therapeutics Neutral

Summary

EQ beats Medicenna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Shoal Games?

Shoal Games (CVE:SGW) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Shoal Games had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 1 mentions for Shoal Games and 0 mentions for Medicenna Therapeutics. Shoal Games' average media sentiment score of 0.67 beat Medicenna Therapeutics' score of 0.34 indicating that Shoal Games is being referred to more favorably in the media.

Company Overall Sentiment
Shoal Games Positive
Medicenna Therapeutics Neutral

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Shoal Games has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Shoal Games' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Shoal GamesN/A N/A N/A
Medicenna Therapeutics -533,640.00%-219.30%-32.80%

Shoal Games has higher revenue and earnings than Medicenna Therapeutics. Shoal Games is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shoal GamesC$106.98K612.86-C$5.25M-C$0.04N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.22N/A

Summary

Shoal Games beats Medicenna Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$36.46MC$517.33MC$7.10BC$13.09B
Dividend YieldN/A3.88%2.67%6.17%
P/E Ratio-1.803.4627.1936.24
Price / SalesN/A6,337.92578.1010.00
Price / Cash1.1513.1349.3482.29
Price / Book13.2889.2910.954.44
Net Income-C$25.98M-C$96.07MC$3.56BC$299.09M
7 Day PerformanceN/A0.14%1.54%0.46%
1 Month Performance-9.20%3.67%6.46%0.41%
1 Year Performance-54.60%66.39%33.22%33.82%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.40
+2.6%		N/A-54.1%C$36.46MN/AN/A20
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/A+122.2%C$126.35MN/AN/A3,150
WMD
WeedMD
N/AC$0.28
-1.8%		N/A+0.0%C$67.82MC$27.53MN/A628
EQ
EQ
N/AC$0.95
+1.1%		N/A-2.1%C$66.11MC$10.54MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 7/8/2026 by MarketBeat.com Staff.
From Our Partners
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel